CLINICAL AND LABORATORY STANDARDS INSTITUTE®

December 2010

QMS12-A

Development and Use of Quality Indicators for Process Improvement and Monitoring of Laboratory Quality; Approved Guideline

This document provides guidance on development of quality indicators and their use in the medical laboratory.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeals Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeals, documented in the CLSI Standards Development Policies and Processes, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: +1.610.688.0100
F: +1.610.688.0700
www.clsi.org
standard@clsi.org

Vol. 30 No. 24
ISBN 1-56238-738-3
Formerly GP35-A
ISSN 0273-3099
Vol. 30 No. 24

Volume 30 Number 24

Development and Use of Quality Indicators for Process Improvement and Monitoring of Laboratory Quality; Approved Guideline

Michael A. Noble, MD, FRCP(C)
Maureen E. Ahler, MSQA, MT(ASCP)
Bette Bennett, RT
Julie Coffey, CQA, CMQ/OE(ASQ), ART, MLT
Kathryn Connolly, MT(ASCP); CQA (ASQ)
Judy A. Daly, PhD
Christine Fleming, BA, MLT
Sonia C. Giribaldi, MT(ASCP)
Lee Hilborne, MD, MPH, FASCP
Elizabeth Kenimer Leibach, EdD, MS, CLS, MT
John J. Mahoney
Barbara Parsons, MA, MT(ASCP)
Charles D. Reynolds, MS
Paul Valenstein, MD

Abstract

Clinical and Laboratory Standards Institute document QMS12-A—*Development and Use of Quality Indicators for Process Improvement and Monitoring of Laboratory Quality; Approved Guideline* provides guidance on development of quality indicators and their use in the medical laboratory. These indicators include measures developed in a single laboratory for local use and indicators developed by other organizations and national bodies. The document includes criteria for development of quantitative, ordinal, and qualitative indicators; it also includes procedures for gathering data, presenting and interpreting results, monitoring performance over time, and comparing performance with other laboratories or national norms.

Clinical and Laboratory Standards Institute (CLSI). *Development and Use of Quality Indicators for Process Improvement and Monitoring of Laboratory Quality; Approved Guideline.* CLSI document QMS12-A (ISBN 1-56238-738-3). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2010.

Suggested Citation

CLSI. *Development and Use of Quality Indicators for Process Improvement and Monitoring of Laboratory Quality; Approved Guideline*. CLSI document QMS12-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.

Proposed Guideline

February 2009

Approved Guideline

December 2010

ISBN 1-56238-738-3
ISSN 0273-3099

Committee Membership

Area Committee on Quality Systems and Laboratory Practices

Carl D. Mottram, BA, RRT, RPFT, FAARC
Chairholder
Mayo Clinic
Rochester, Minnesota, USA

Devery Howerton, PhD
Vice-Chairholder
Centers for Disease Control and Prevention
Atlanta, Georgia, USA

Eric Arendash, MT(ASCP)
Centers for Medicare & Medicaid Services
Philadelphia, Pennsylvania, USA

Lucia M. Berte, MA, MT(ASCP)SBB, DLM; CQA(ASQ) CQM/OE
Laboratories Made Better!
Broomfield, Colorado, USA

Theresa Billups, MBA, MT(ASCP)DLM
Remel, Inc.
Lake Charles, Louisiana, USA

Michael B. Cohen, MD
University of Iowa
Iowa City, Iowa, USA

Nancy Dubrowny, MS, MT(ASCP)SC
BD Preanalytical Systems
Franklin Lakes, New Jersey, USA

Michelle Jenkins, MS, MT(AMT) ASQ, CQE
Abbott Diagnostics
Irving, Texas, USA

Jennifer Schiffgens, MBA, MT(ASCP), CLS
California Pacific Medical Center
San Francisco, California, USA

Bruce D. Tually, BAppSc, MAppSc
Hunter Area Pathology Service
New South Wales, Australia

Tonya Wilbon, BS, M(ASCP)
FDA Center for Devices/Radiological Health
Rockville, Maryland, USA

Advisors

Susan Blonshine, RRT, RPFT, FAARC
TechEd Consultants, Inc.
Mason, Michigan, USA

Dennis J. Ernst, MT(ASCP)
Center for Phlebotomy Education
Corydon, Indiana, USA

Mark D. Kolins, MD
William Beaumont Hospital
Royal Oak, Michigan, USA

Michael A. Noble, MD, FRCP(C)
University of British Columbia
Vancouver, Canada

Albert Rabinovitch, MD, PhD
NovoMetrics, Inc.
Mountain View, California, USA

Stephen J. Sarewitz, MD
Eastside Pathology Inc., PS
Bellevue, Washington, USA

Carol A. Walker
Siemens Healthcare Diagnostics
Walpole, Massachusetts, USA

Thomas L. Williams, MD
Nebraska Methodist Hospital
Omaha, Nebraska, USA

Sheila M. Woodcock, MBA, FCSMLS(D)
QSE Consulting
Rose Bay, Nova Scotia, Canada

Acknowledgment

CLSI gratefully acknowledges the following individuals and organizations for their help in preparing this approved-level guideline:

Maureen E. Ahler, MSQA, MT(ASCP), Kaiser Permanente Medical Care

Bette Bennett, RT, LifeLabs Medical Laboratory Services

Julie Coffey, CQA, CMQ/OE(ASQ), ART, MLT, Quality Management Program – Laboratory Services

Sonia C. Giribaldi, MT(ASCP), Alfred I. DuPont Hospital for Children

Elizabeth Kenimer Leibach, EdD, MS, CLS, MT, Medical College of Georgia

Contents

Contents (Continued)

Foreword

With increasing awareness, the impact of medical errors can be seen on patient safety. Medical errors can result in annoyance and inconvenience such as time lost or necessitated patient revisits, but can also result in the more serious consequences of diagnostic delay or error, increased cost, inappropriate therapy, and worse, increased risk of patient illness, debility, and sometimes death. Medical errors occur throughout the health care process, in the clinical setting and also in the laboratory. An active program of quality management allows the laboratory to monitor for error with the intended goals of early detection and rapid remediation and correction, and more importantly, prevention of errors before they occur.

The process of monitoring for and addressing error does not just happen. Quality takes time to define. It requires planning of the processes and procedures that develop appropriate, measurable, interpretable information upon which action can take place in the cycle of continuous improvement. Those procedures can be referred to as quality indicators. Quality indicators are an integral component of all quality management systems, including ISO 9001,[1] ISO 15189,[2] and ISO 17025,[3] and the system described within CLSI document HS01.[4] Ideally the development of quality indicators should be based on both a risk assessment of potential errors and the frequency of observed errors.

Importantly, not all quality indicators are derived within the laboratory or are even laboratory centric. Many are recommended or required over a broader regional, state, or national network of laboratories or health care systems, based on voluntary participation, best practice recommendation, organizational mandate, or regulatory requirement. This document provides guidance in selecting and applying indicators that are developed in a single laboratory for local use and indicators developed by other organizations and national bodies.

Many organizations can benefit from guidance on selecting and developing the quality indicators they use. Experience demonstrates that poorly designed indicators can result in confusing and misleading information that leads less towards continual improvement, and more towards increased work, and often poor decision making. Others, while well designed and intended, are impractical because some laboratories do not have the resources to gather the actual information required, or do not have the capability or resources for following through with an appropriate action plan. Finally, some laboratories continue to collect information on parameters that are highly stable, rather than shift their focus, time, and energy to other indicators that may provide information that leads to change. Failure to recognize the value of information gathered is both ineffective and inefficient. The goal of this document is to highlight an effective approach to selection, development, interpretation, and application of information derived from well-designed quality indicators.

NOTE:

This document provides guidance in selecting and applying indicators that are developed in a single laboratory for local use and indicators developed by other organizations and national bodies.

IMPORTANT NOTE:

Poorly designed indicators **can result in confusing and misleading information that leads less towards continual improvement, and more towards increased work,** and often poor decision making.

KEY WORDS

Continual improvement

Corrective actions

Evidence-based decision making

Management review

Measurement

Metrics

Preventive action

Quality control

Quality indicator

Quality management system

Remedial actions

This page is intentionally left blank.

Introductory Chapters

These chapters include:

1. **Scope**
   - Document scope and applicable exclusions
2. **Introduction**
   - Introductory and background information pertinent to the document content
3. **Terminology**
   - Terms and definitions used in the document
   - Abbreviations and acronyms used in the document